Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Meningococcal Polysaccharide Diphtheria Protein Conjugate · 1 trial · 2 indications
| Arm | Type | Description |
|---|---|---|
| Vaccinated at Age 9 and 12 Months | EXPERIMENTAL | Participants received Menactra® vaccine at 9 and 12 Months of age |
| Vaccinated at Age 9 and 15 Months | EXPERIMENTAL | Participants received Menactra® vaccine at 9 and 15 Months of age |
| Vaccinated at Age 12 and 15 Months | EXPERIMENTAL | Participants received Menactra® vaccine at Age 12 and 12 Months of age |
| Vaccinated at Age 15 Months | EXPERIMENTAL | Participants received Menactra® vaccine at 15 Months of age |
| Vaccinated at Age 18 Months | EXPERIMENTAL | Participants received Menactra® vaccine at 18 Months of age |
| Vaccinated at Age 3 Years to <6 Years | ACTIVE_COMPARATOR | Participants received Menomune® vaccine at Age 3 years to \<6 years of age |
| Name | Type | Description |
|---|---|---|
| Meningococcal Polysaccharide Diphtheria Protein Conjugate (Menactra®) | BIOLOGICAL | 0.5 mL, Intramuscular (at age 9 and 12 months) |
| A/C/Y/W-135, Meningococcal Polysaccharide Vaccine (Menomune®) | BIOLOGICAL | 0.5 mL, Subcutaneous (at 3 years to \<6 years of age) |
Inclusion Criteria : * Aged either 9, 12, 15 or 18 months of age or 3 to \< 6 years of age on the day of inclusion. * Informed consent form that has been approved by the site's Institutional Review Board (IRB) and signed by the parent or legal guardian * Able to attend all scheduled visits and to c...